Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

J. Schetelig, LC. de Wreede, M. van Gelder, L. Koster, J. Finke, D. Niederwieser, D. Beelen, GJ. Mufti, U. Platzbecker, A. Ganser, S. Heidenreich, J. Maertens, G. Socié, A. Brecht, M. Stelljes, G. Kobbe, L. Volin, A. Nagler, A. Vitek, T. Luft, P....

. 2019 ; 33 (3) : 686-695. [pub] 20181220

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19027976

The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19027976
003      
CZ-PrNML
005      
20190815105429.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-018-0302-y $2 doi
035    __
$a (PubMed)30573777
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schetelig, Johannes $u Universitaetsklinikum Dresden, Dresden, Germany. Johannes.Schetelig@uniklinikum-dresden.de. DKMS Clinical Trials Unit, Dresden, Germany. Johannes.Schetelig@uniklinikum-dresden.de.
245    10
$a Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia / $c J. Schetelig, LC. de Wreede, M. van Gelder, L. Koster, J. Finke, D. Niederwieser, D. Beelen, GJ. Mufti, U. Platzbecker, A. Ganser, S. Heidenreich, J. Maertens, G. Socié, A. Brecht, M. Stelljes, G. Kobbe, L. Volin, A. Nagler, A. Vitek, T. Luft, P. Ljungman, I. Yakoub-Agha, M. Robin, N. Kröger,
520    9_
$a The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.
650    _2
$a senioři $7 D000368
650    _2
$a příčina smrti $7 D002423
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x mortalita $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a akutní myeloidní leukemie $x mortalita $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myelodysplastické syndromy $x mortalita $7 D009190
650    _2
$a sekundární malignity $x mortalita $7 D016609
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a příprava pacienta k transplantaci $x mortalita $7 D019172
650    _2
$a homologní transplantace $x mortalita $7 D014184
655    _2
$a časopisecké články $7 D016428
700    1_
$a de Wreede, Liesbeth C $u DKMS Clinical Trials Unit, Dresden, Germany. Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a van Gelder, Michel $u University Hospital Maastricht, Maastricht, The Netherlands.
700    1_
$a Koster, Linda $u EBMT Data Office Leiden, Leiden, The Netherlands.
700    1_
$a Finke, Jürgen $u University of Freiburg, Freiburg, Germany.
700    1_
$a Niederwieser, Dietger $u University Hospital Leipzig, Leipzig, Germany.
700    1_
$a Beelen, Dietrich $u University Hospital, Essen, Germany.
700    1_
$a Mufti, G J $u GKT School of Medicine, London, UK.
700    1_
$a Platzbecker, Uwe $u Universitaetsklinikum Dresden, Dresden, Germany.
700    1_
$a Ganser, Arnold $u Hannover Medical School, Hannover, Germany.
700    1_
$a Heidenreich, Silke $u University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Maertens, Johan $u University Hospital Gasthuisberg, Leuven, Belgium.
700    1_
$a Socié, Gerard $u Hopital St. Louis, Paris, France.
700    1_
$a Brecht, Arne $u Deutsche Klinik für Diagnostik, Wiesbaden, Germany.
700    1_
$a Stelljes, Matthias $u University of Münster, Münster, Germany.
700    1_
$a Kobbe, Guido $u Heinrich Heine Universität, Düsseldorf, Germany.
700    1_
$a Volin, Liisa $u HUCH Comprehensive Cancer Center, Helsinki, Finland.
700    1_
$a Nagler, Arnon $u Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Vitek, Antonin $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Luft, Thomas $u University of Heidelberg, Heidelberg, Germany.
700    1_
$a Ljungman, Per $u Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France.
700    1_
$a Robin, Marie $u Hopital St. Louis, Paris, France.
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 33, č. 3 (2019), s. 686-695
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30573777 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190815105656 $b ABA008
999    __
$a ok $b bmc $g 1433125 $s 1066436
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 33 $c 3 $d 686-695 $e 20181220 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace